Obesity associated with defects in leptin-melanocortin pathway

Clinical trials for Obesity associated with defects in leptin-melanocortin pathway explained in plain language.

Never miss a new study

Get alerted when new Obesity associated with defects in leptin-melanocortin pathway trials appear

Sign up with your email to follow new studies for Obesity associated with defects in leptin-melanocortin pathway, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

Hope for rare obesity: setmelanotide tested for long-term safety

Disease control Completed

This study looks at the long-term safety of setmelanotide (Imcivree) in 30 people aged 2 and older with rare genetic obesity. Participants have already completed a previous setmelanotide study and shown benefit. They will receive daily injections to see if the drug remains safe a…

Matched conditions: OBESITY ASSOCIATED WITH DEFECTS IN LEPTIN-MELANOCORTIN PATHWAY

Phase 3 • Sponsor: Rhythm Pharmaceuticals, Inc. • Aim: Disease control

Last updated Jul 17, 2026 00:00 UTC

Obesity associated with defects in leptin-melanocortin pathway

Get alerted when new Obesity associated with defects in leptin-melanocortin pathway trials appear

Hope for rare obesity: setmelanotide tested for long-term safety